VYGR
Voyager Therapeutics Inc
2.80$
-2.4%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 560.5% | 1.5% | 6.1% | 108.0% | 122.8% | 522.6% | 487.0% | 602.5% | 268.4% | 218.8% | 35.9% | – | – | |
| -460.5% | 98.5% | 93.9% | -8.0% | -22.8% | -422.6% | -387.0% | -502.5% | -168.4% | -118.8% | 64.1% | 100.0% | -104.2% | |
| 560.5% | 27.1% | 132.7% | 116.5% | 122.8% | 566.8% | 487.0% | 602.5% | 268.4% | 234.4% | 948.8% | 696.4% | 343.8% | |
| 179.0% | 11.4% | 44.1% | 34.3% | 33.2% | 143.3% | 148.9% | 201.8% | 60.6% | 53.6% | 318.6% | 237.5% | 93.1% | |
| 179.0% | 38.5% | 176.8% | 42.8% | 33.2% | 187.5% | 148.9% | 201.8% | 60.6% | 76.4% | 1,231.4% | 933.9% | 235.9% | |
| -639.5% | 60.0% | -82.9% | -50.8% | -56.0% | -610.1% | -536.0% | -704.3% | -228.9% | -195.2% | -1,167.4% | -833.9% | -340.1% | |
| -557.5% | 63.5% | -58.0% | -34.2% | -36.5% | -540.0% | -478.7% | -641.7% | -208.1% | -178.8% | -1,076.9% | -772.6% | -312.3% | |
| 3.8% | 0.9% | 0.1% | 0.1% | 0.2% | 9.3% | 0.6% | 0.3% | 0.6% | 0.1% | 0.5% | 0.6% | 0.4% | |
| -561.4% | 62.6% | -58.1% | -34.3% | -36.7% | -549.3% | -479.2% | -642.0% | -208.7% | -178.8% | -1,077.4% | -773.2% | -312.6% | |
| -537.0% | 65.0% | -51.9% | -37.6% | -32.0% | -523.9% | -463.0% | -621.2% | -201.1% | -171.9% | -1,040.9% | -714.5% | -298.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.